Abstract: Provided herein are methods of detecting lipids in humans suspected of having cancer, in particular detecting lipids in samples from a human suspected of having breast or lung cancer.

Abstract: Methods to determine the absence or presence of one or more cancer types in an animal are disclosed herein. In some embodiments, amounts of lipids in a sample (e.g., a bodily fluid or treatment thereof) from the animal are used with a predictive model to make the determination. The lipid amounts can be measured, in some instances, using a mass spectrometry system.

Abstract: Provided herein are methods of detecting lipids in humans suspected of having cancer, in particular detecting lipids in samples from a human suspected of having breast or lung cancer.

Abstract: A chemical pre-concentrator is provided having a support structure, an airflow conduit, and a layer of a reactive chemical compound on a surface of the support structure is used for collecting and pre-concentrating at least one chemical analyte from a dilute sample. A method of concentrating a gaseous sample is provide that includes exposing the chemical pre-concentrator with a dilute gaseous sample that contains at least one chemical analyte; and forming a conjugate of the at least one chemical analyte. A method of diagnosing a disease state in a mammalian patient is provided using the chemical pre-concentrator.

Abstract: Methods to determine the absence or presence of one or more cancer types in an animal are disclosed herein. In some embodiments, amounts of lipids in a sample (e.g., a bodily fluid or treatment thereof) from the animal are used with a predictive model to make the determination. The lipid amounts can be measured, in some instances, using a mass spectrometry system.

Abstract: Some embodiments of the invention include methods for detecting the presence of cancer in animal tissue in an animal that was administered a labeled molecule. Some of the methods disclosed comprise obtaining an NMR spectrum, an MS spectrum, or both. In some instances, spectra can be taken of a cancer cell extract of the tissue and of a non-cancer cell extract of the tissue. In some embodiments, the amounts of at least one resultant labeled molecule (e.g., a molecule resulting from transformation of the administered labeled molecule) from each extract can be compared to detect the presence of cancer.